Vonoprazan

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND Vonoprazan (VPZ) is a novel potassium-competitive acid blocker that may be clinically beneficial for proton pump… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2016
2016
2016
BACKGROUND Vonoprazan is a novel potassium-competitive acid blocker which may provide clinical benefit in acid-related disorders… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2016
2016
BACKGROUND Acid inhibitory effects of proton pump inhibitors (PPIs) are influenced by CYP2C19 genotype. In contrast, the potent… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2016
2016
BACKGROUND Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal… (More)
Is this relevant?
2015
2015
A potent, rapid acting potassium-competitive acid blocker, vonoprazan, is introduced for clinical use in Japan. A number of phase… (More)
Is this relevant?
Review
2015
Review
2015
Vonoprazan (Takecab®) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Proton pump inhibitors (PPIs) are widely used for the treatment of acid-related diseases. Vonoprazan is a member of a… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2015
2015
BACKGROUND TAK-438 (vonoprazan) is a potassium-competitive acid blocker that reversibly inhibits gastric H(+) , K(+) -ATPase… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2015
2015
BACKGROUND The gastric H(+) ,K(+) -ATPase is the preferred target for acid suppression. Until recently, the only drugs that… (More)
Is this relevant?